Top Market Shifts Transforming the Glycomic Therapeutics Market Landscape: Key Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Glycomic Therapeutics Market Through 2025?
There has been a quick expansion of the glycomic therapeutics market size in the last few years. The market is projected to escalate from $164.71 billion in 2024 to $190.03 billion in 2025, with a compound annual growth rate (CAGR) of 15.4%. The considerable growth observed in the previous period is due to higher awareness about the importance of glycan, an increase in chronic illnesses, the development of drugs for rare diseases, and collaborations in glycomics research.

What's the Projected Size of the Global Glycomic Therapeutics Market by 2029?
In the coming years, a swift progression is anticipated in the size of the glycomic therapeutics market. It's projected to escalate to a worth of $361.09 billion by 2029, increasing at a compound annual growth rate (CAGR) of 17.4%. This growth throughout the forecasting period can be credited to the broadening understanding of glycan biology, precision medicine methodologies, a growing fascination in immunotherapy, increased monetary injections into research for rare diseases, and the emergence of glycan biomarkers. Significant trends within the forecast period incorporate the expansion of glycomic applications in the oncology field, glycoengineering's role in enhancing therapeutic proteins, glycomics' inclusion in immuno-oncology, the application of glycomics to rare and genetic disorders, and regulatory considerations for glycomic drugs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Top Growth Drivers in the Glycomic Therapeutics Industry: What's Accelerating the Market?
The escalation in diabetes cases is anticipated to stimulate the expansion of the glycomic therapeutics market. Diabetes, a persistent health condition, disrupts the body's control over blood sugar (glucose) levels. Diabetes has been noted to cause changes in glycans, potentially leading to insulin resistance and other metabolic malfunctions. Unique glycan patterns are used as biomarkers for the detection of diabetes, projecting its acceleration, and tracking responses to treatments. For example, the IDF Diabetes Atlas from Belgium, a worldwide resource offering detailed data on diabetes prevalence, projected in March 2022 that the worldwide prevalence of diabetes would rise from 643 million in 2030 to 783 million by 2045, surging by 140 million cases. Consequently, the escalating prevalence of diabetes is fueling the expansion of the glycomic therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11894&type=smp

What Trends Will Shape the Glycomic Therapeutics Market Through 2029 and Beyond?
The emergence of product innovation is noticeably shaping trends in the glycomic therapeutics market. Companies dominating this sector are intensifying their market foothold by focusing on creating and developing technologically advanced and innovative solutions. For example, Glenmark Pharmaceuticals Limited, originating from India and specialising in advanced therapies, introduced an innovative fixed-dose combination (FDC) of a DPP4 inhibitor, namely Teneligliptin, along with Pioglitazone in April 2022. This combination is aimed at enhancing glycemic control and decreasing insulin resistance in patients suffering from type 2 diabetes.

What Are the Main Segments in the Glycomic Therapeutics Market?
The glycomic therapeutics market covered in this report is segmented -

1) By Class: Isolated, Synthetic
2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures
3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action
4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher's Disease, Mps-1 And IV, Cancer, Alzheimer's Disease, Influenza Type A And B, Other Indications

Subsegments:
1) By Isolated: Natural Glycans, Glycan Derivatives, Glycoproteins
2) By Synthetic: Chemically Synthesized Glycans, Recombinant Glycans, Glycopeptides

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11894&type=smp

Which Top Companies are Driving Growth in the Glycomic Therapeutics Market?
Major companies operating in the glycomic therapeutics market include F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, ICON plc, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd, Z Biotech LLC, Alzheon Inc., GlycoMar Limited

Which Regions Will Dominate the Glycomic Therapeutics Market Through 2029?
North America was the largest region in the glycomic therapeutics in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11894

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.